Neurodon
neurodon.net
Actively hiring
Professional Services
Biotechnology
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$500k
1 round on record
Latest round
$500k
Venture round · Oct 2019 · 6 yr ago
Backers
1
Elevate Ventures
The money's age
Long since its last round
83 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 3, 2022
Partnership JDRF and Neurodon Partner to Advance Small Molecules Targeting a Key Pathway in Type 1 Diabetes Progression · neurodon.net
Oct 3, 2019
Raised a round Venture round $500k · SEC Form D
2019
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Oct 2019 | $500k | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Neurodon Corp | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Russell DahlExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Elevate Ventures Similar startupsby what they do, their industry and backers
Restoring energy. Next-generation disease-modifying medicines for ALS and Parkinson's.
Lario Therapeutics are developing first-in-class disease modifying treatments for severe neurological disorders. Precision Neuroscience…
Over two billion women globally suffer from uterine diseases that impact the endometrium. We’re here to change that.
Nanopath has developed deep technological breakthroughs that have the potential to change the molecular diagnostic paradigm.
Engineering therapeutics that adapt with cellular regulation to eliminate disease.
Revel Pharmaceuticals develops therapeutic enzymes that reverse age-related damage in structural tissue, targeting the molecular root of…
News
New study published in The Journal of Neuroscience highlights disease-modifying potential of Neurodon's SERCA activators for Alzheimer's disease
Alzheimer's disease (AD) is a prevalent neurodegenerative disorder characterized by disrupted calcium signaling, synaptic dysfunction, and cognitive decline. Dysregulated calcium signaling is a key driver of AD pathogenesis, but previous efforts targeting
Read more
Report
Neurodon CEO Dr. Russell Dahl to Present at the 20th FASEB Conference on Calcium and Cell Function
Neurodon Corp., a leader in the development of therapeutics targeting calcium homeostasis, is proud to announce that its CEO, Russell Dahl, Ph.D., will present at the 20th FASEB Conference on Calcium and Cell Function held in Winnipeg, Canada on July 6 -
Read more
Report
Accomplished Biotech Executive Frederick Beddingfield III, M.D., Ph.D. Joins Neurodon's Board
Accomplished Biotech Executive Frederick Beddingfield III, M.D., Ph.D. Joins Neurodon's Board of Directors CROWN POINT, Ind., June 11, 2025 (GLOBE NEWSWIRE) - Neurodon Corp., a leader in the development of endoplasmic reticulum (ER) stress-targeted therap
Read more
Report
Accomplished Biotech Executive Frederick Beddingfield III, M.D., Ph.D. Joins Neurodon's Board of Directors
CROWN POINT, Ind., June 11, 2025 (GLOBE NEWSWIRE) -- Neurodon Corp., a leader in the development of endoplasmic reticulum (ER) stress-targeted therapeutics for diabetes and neurodegeneration, welcomes Frederick Beddingfield, III, M.D., Ph.D., a 22-year ve
Read more
Report
Neurodon Joins the Longevity Biotechnology Association (LBA)
There is a growing body of evidence that aberrant cellular calcium homeostasis, ER stress, and the UPR are correlated with aging and age-associated diseases such as neurodegeneration. Since Neurodon's focus is on correcting this dysfunction, we envision l
Read more
Report
Pro access
Upgrade to see all 14 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
People
Russell Dahl
Executive Officer, Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Crown Point
United States
HQ
Contact Us
9800 Connecticut Dr., Crown Point, IN 46307
Financials
Total raised
$500k
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2019 | $500k | Details |